1.Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
Ja Min BYUN ; Sung-Soo PARK ; Sung-Soo YOON ; Ari AHN ; Myungshin KIM ; Jung Yeon LEE ; Young-Woo JEON ; Seung-Hwan SHIN ; Seung-Ah YAHNG ; Youngil KOH ; Chang-Ki MIN
Blood Research 2023;58(2):83-90
Background:
The goal of induction therapy for multiple myeloma (MM) is to achieve adequate disease control. Current guidelines favor triplet (bortezomib-lenalidomide-dexamethasone;VRd) or quadruplet regimens (daratumumab, bortezomib-thalidomide-dexamethasone;D-VTd). In the absence of a direct comparison between two treatment regimens, we conducted this study to compare the outcomes and safety of VRd and D-VTd.
Methods:
Newly diagnosed MM patients aged >18 years who underwent induction therapy followed by autologous stem cell transplantation (ASCT) between November 2020 and December 2021 were identified. Finally, patients with VRd (N=37) and those with D-VTd (N=43) were enrolled.
Results:
After induction, 10.8% of the VRd group showed stringent complete remission (sCR), 21.6% showed complete response (CR), 35.1% showed very good partial response (VGPR), and 32.4% showed partial response (PR). Of the D-VTd group, 9.3% showed sCR, 34.9% CR, 48.8% VGPR, and 4.2% PR (VGPR or better: 67.6% in VRd vs. 93% in D-VTd, P =0.004). After ASCT, 68.6% of the VRd group showed CR or sCR, while 90.5% of the D-VTd group showed CR or sCR (P=0.016). VRd was associated with an increased incidence of skin rash (P=0.044). Other than rashes, there were no significant differences in terms of adverse events between the two groups.
Conclusion
Our study supports the use of a front-line quadruplet induction regimen containing a CD38 monoclonal antibody for transplant-eligible patients with newly diagnosed MM.
4.Clinicopathologic and Oncological Outcomes in Korean Men With Advanced Metastatic Testicular Cancer Undergoing Postchemotherapeutic Retroperitoneal Lymph Node Dissection.
Hyeong Dong YUK ; Minyong KANG ; Jung Keun LEE ; Sung Kyu HONG ; Ja Hyeon KU ; Seok Soo BYUN ; Cheol KWAK ; Hyeon Hoe KIM ; Sang Eun LEE ; Chang Wook JEONG
Korean Journal of Urological Oncology 2017;15(3):143-151
PURPOSE: To evaluate the clinicopathologic and oncological outcomes of advanced metastatic testicular cancer in Korean men who underwent retroperitoneal lymph node dissection (RPLND) following chemotherapy. MATERIALS AND METHODS: Data of 26 patients with testicular cancer who underwent RPLND after chemotherapy at 2 hospitals in Korea between September 2004 and June 2016 were retrospectively analyzed. Clinical and histopathological variables such as stage of the testicular cancer, age of the patients during surgery, size of the retroperitoneal lymph nodes (RPLNs), histopathological results, duration and complications related to the surgery, cancer recurrence, and mortality were analyzed. RESULTS: During testicular surgery, the T stage was pT1, pT2, and pT3 in 50% (n=13), 26.9% (n=7), and 15.3% (n=4) of the patients, respectively. Mixed germ cell tumor was the most common finding, seen in 73.1% (n=19) of patients. The indications for RPLND were residual lymph nodes after chemotherapy, 84.6% (n=22); and disease progression and remission, 7.7% (n=2). Pathological analysis revealed viable tumors in 19.2% of patients (n=5), necrotic/fibrotic tissue in 42.3% (n=11), and teratoma in 34.6% (n=9). Intraoperative and postoperative complications occurred in 23.1% (n=6) and 19.2% of patients (n=5). The median duration of follow-up was 27.5 months (interquartile range, 1.3–108.2 months); 11.5% (n=3) patients had recurrence, and 3.8% (n=1) died of progressive metastatic testicular cancer. CONCLUSIONS: Viable germ cell tumors were present in 19.2% of patients with testicular cancer who underwent RPLND after chemotherapy. This is the first study of its kind in the Korean population.
Disease Progression
;
Drug Therapy
;
Follow-Up Studies
;
Humans
;
Korea
;
Lymph Node Excision*
;
Lymph Nodes*
;
Male
;
Mortality
;
Neoplasms, Germ Cell and Embryonal
;
Postoperative Complications
;
Recurrence
;
Retrospective Studies
;
Teratoma
;
Testicular Neoplasms*
5.The Association between End-of-Life Care and the Time Interval between Provision of a Do-Not-Resuscitate Consent and Death in Cancer Patients in Korea.
Sun Kyung BAEK ; Hye Jung CHANG ; Ja Min BYUN ; Jae Joon HAN ; Dae Seog HEO
Cancer Research and Treatment 2017;49(2):502-508
PURPOSE: We explored the relationship between the use of each medical intervention and the length of time between do-not-resuscitate (DNR) consent and death in Korea. MATERIALS AND METHODS: A total of 295 terminal cancer patients participated in this retrospective study. Invasive interventions (e.g., cardiopulmonary resuscitation, intubation, and hemodialysis), less invasive interventions (e.g., transfusion, antibiotic use, inotropic use, and laboratory tests), and the time interval between the DNR order and death were evaluated. The subjects were divided into three groups based on the amount of time between DNR consent and death (G1, time interval ≤ 1 day; G2, time interval > 1 day to ≤ 3 days; and G3, time interval > 3 days). RESULTS: In general, there were fewer transfusions and laboratory tests near death. Invasive interventions tended to be implemented only in the G1 group. There was also less inotrope use and fewer laboratory tests in the G3 group than G1 and G2. Moreover, the G3 group received fewer less invasive interventions than those in G1 (odds ratio [OR], 0.16; 95% confidence interval [CI], 0.03 to 0.84; 3 days before death, and OR, 0.16; 95% CI, 0.04 to 0.59; the day before death). The frequency of less invasive interventions both 1 and 3 days before death was significantly lower for the G3 group than the G1 (p ≤ 0.001) and G2 group compared to G1 (p=0.001). CONCLUSION: Earlier attainment of DNR permission was associated with reduced use of medical intervention. Thus, physicians should discuss death with terminal cancer patients at the earliest practical time to prevent unnecessary and uncomfortable procedures and reduce health care costs.
Cardiopulmonary Resuscitation
;
Health Care Costs
;
Humans
;
Intubation
;
Korea*
;
Resuscitation Orders
;
Retrospective Studies
;
Terminal Care
6.The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-alpha Blockers.
Ja Min BYUN ; Chang Kyun LEE ; Sang Youl RHEE ; Hyo Jong KIM ; Jung Wook KIM ; Jae Jun SHIM ; Jae Young JANG
Journal of Korean Medical Science 2015;30(2):173-179
The aims of this study were to assess the risk of tuberculosis (TB) and the status of latent tuberculosis infection (LTBI) in Korean patients with inflammatory bowel disease (IBD) receiving tumor necrosis factor (TNF)-alpha blockers. We reviewed medical records of 525 Korean IBD patients (365 TNF-alpha blocker naive and 160 TNF-alpha blocker exposed) between January 2001 and December 2013. The crude incidence of TB was significantly higher in IBD patients receiving TNF-alpha blockers compared to TNF-alpha-blocker-naive patients (3.1% vs. 0.3%, P=0.011). The mean incidence of TB per 1,000 patient-years was 1.84 for the overall IBD population, 4.89 for TNF-alpha blocker users, and 0.45 for TNF-alpha-blocker-naive patients. The adjusted risk ratio of TB in IBD patients receiving TNF-alpha blocker was 11.7 (95% confidence interval, 1.36-101.3). Pulmonary TB was prevalent in patients treated with TNF-alpha blockers (80.0%, 4/5). LTBI was diagnosed in 17 (10.6%) patients, and none of the 17 LTBI patients experienced reactivation of TB during treatment with TNF-alpha blockers. Treatment with TNF-alpha blockers significantly increased the risk of TB in IBD patients in Korea. De novo pulmonary TB infection was more prevalent than reactivation of LTBI, suggesting an urgent need for specific recommendations regarding TB monitoring during TNF-alpha blocker therapy.
6-Mercaptopurine/adverse effects/analogs & derivatives/therapeutic use
;
Adult
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
;
Antibodies, Monoclonal/adverse effects/therapeutic use
;
Cohort Studies
;
Colitis, Ulcerative/*drug therapy
;
Crohn Disease/*drug therapy
;
Female
;
Humans
;
Latent Tuberculosis/chemically induced/diagnosis/*epidemiology
;
Male
;
Mycobacterium tuberculosis/isolation & purification
;
Republic of Korea
;
Retrospective Studies
;
Tuberculosis, Pulmonary/chemically induced/diagnosis/*epidemiology
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
7.The Risk of Tuberculosis in Korean Patients with Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-alpha Blockers.
Ja Min BYUN ; Chang Kyun LEE ; Sang Youl RHEE ; Hyo Jong KIM ; Jung Wook KIM ; Jae Jun SHIM ; Jae Young JANG
Journal of Korean Medical Science 2015;30(2):173-179
The aims of this study were to assess the risk of tuberculosis (TB) and the status of latent tuberculosis infection (LTBI) in Korean patients with inflammatory bowel disease (IBD) receiving tumor necrosis factor (TNF)-alpha blockers. We reviewed medical records of 525 Korean IBD patients (365 TNF-alpha blocker naive and 160 TNF-alpha blocker exposed) between January 2001 and December 2013. The crude incidence of TB was significantly higher in IBD patients receiving TNF-alpha blockers compared to TNF-alpha-blocker-naive patients (3.1% vs. 0.3%, P=0.011). The mean incidence of TB per 1,000 patient-years was 1.84 for the overall IBD population, 4.89 for TNF-alpha blocker users, and 0.45 for TNF-alpha-blocker-naive patients. The adjusted risk ratio of TB in IBD patients receiving TNF-alpha blocker was 11.7 (95% confidence interval, 1.36-101.3). Pulmonary TB was prevalent in patients treated with TNF-alpha blockers (80.0%, 4/5). LTBI was diagnosed in 17 (10.6%) patients, and none of the 17 LTBI patients experienced reactivation of TB during treatment with TNF-alpha blockers. Treatment with TNF-alpha blockers significantly increased the risk of TB in IBD patients in Korea. De novo pulmonary TB infection was more prevalent than reactivation of LTBI, suggesting an urgent need for specific recommendations regarding TB monitoring during TNF-alpha blocker therapy.
6-Mercaptopurine/adverse effects/analogs & derivatives/therapeutic use
;
Adult
;
Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use
;
Antibodies, Monoclonal/adverse effects/therapeutic use
;
Cohort Studies
;
Colitis, Ulcerative/*drug therapy
;
Crohn Disease/*drug therapy
;
Female
;
Humans
;
Latent Tuberculosis/chemically induced/diagnosis/*epidemiology
;
Male
;
Mycobacterium tuberculosis/isolation & purification
;
Republic of Korea
;
Retrospective Studies
;
Tuberculosis, Pulmonary/chemically induced/diagnosis/*epidemiology
;
Tumor Necrosis Factor-alpha/*antagonists & inhibitors
8.Involvement of Transglutaminase-2 in alpha-MSH-Induced Melanogenesis in SK-MEL-2 Human Melanoma Cells.
Hyun Ji KIM ; Hye Ja LEE ; Mi Kyung PARK ; Kyung Jin GANG ; Hyun Jung BYUN ; Jeong Ho PARK ; Mi Kyung KIM ; Soo Youl KIM ; Chang Hoon LEE
Biomolecules & Therapeutics 2014;22(3):207-212
Skin hyperpigmentation is one of the most common skin disorders caused by abnormal melanogenesis. The mechanism and key factors at play are not fully understood. Previous reports have indicated that cystamine (CTM) inhibits melanin synthesis, though its molecular mechanism in melanogenesis remains unclear. In the present study, we investigated the effect of CTM on melanin production using ELISA reader and the expression of proteins involved in melanogenesis by Western blotting, and examined the involvement of transglutaminase-2 (Tgase-2) in SK-MEL-2 human melanoma cells by gene silencing. In the results, CTM dose-dependently suppressed melanin production and dendrite extension in alpha-MSH-induced melanogenesis of SK-MEL-2 human melanoma cells. CTM also suppressed alpha-MSH-induced chemotactic migration as well as the expressions of melanogenesis factors TRP-1, TRP-2 and MITF in alpha-MSH-treated SK-MEL-2 cells. Meanwhile, gene silencing of Tgase-2 suppressed dendrite extension and the expressions of TRP-1 and TRP-2 in alpha-MSH-treated SK-MEL-2 cells. Overall, these findings suggested that CTM suppresses alpha-MSH-induced melanogenesis via Tgase-2 inhibition and that therefore, Tgase-2 might be a new target in hyperpigmentation disorder therapy.
Blotting, Western
;
Cystamine
;
Dendrites
;
Enzyme-Linked Immunosorbent Assay
;
Gene Silencing
;
Humans
;
Hyperpigmentation
;
Melanins
;
Melanoma*
;
Skin
9.Upper Gastrointestinal Hemorrhage from Esophageal Ulcer Caused by Coinfection of Herpes Simplex Virus and Cytomegalovirus in Immunocompromised Patient.
Hoe Hoon CHUNG ; Jae Young JANG ; Ja Min BYUN ; Sun Hee PARK ; Dong Hyun KIM ; Young Woon CHANG
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2013;13(1):69-72
Coinfection with herpes simplex virus and cytomegalovirus is a very rare cause of esophageal ulcer and upper gastrointestinal hemorrhage. A 26 year-old male kidney transplant recipient was referred with a complaint of melena. Upper gastrointestinal endoscopy showed a huge esophageal ulcer in the anastomosis site of the esophagogastrostomy. The ulcer occupied about two-thirds of the circumference of the esophageal lumen and an exposed vessel in the ulcer base was noted. Pathologic findings with immunohistochemical stain showed co-infection of herpes simplex virus and cytomegalovirus. He was treated successfully with endoscopic hemostasis and antiviral therapy. We report a case of upper gastrointestinal hemorrhage from esophageal ulcer caused by coinfection of herpes simplex virus and cytomegalovirus.
Coinfection
;
Cytomegalovirus
;
Endoscopy, Gastrointestinal
;
Gastrointestinal Hemorrhage
;
Glycosaminoglycans
;
Hemostasis, Endoscopic
;
Herpes Simplex
;
Humans
;
Immunocompromised Host
;
Kidney
;
Male
;
Melena
;
Methylmethacrylates
;
Polystyrenes
;
Simplexvirus
;
Ulcer
10.Upper Gastrointestinal Hemorrhage from Esophageal Ulcer Caused by Coinfection of Herpes Simplex Virus and Cytomegalovirus in Immunocompromised Patient.
Hoe Hoon CHUNG ; Jae Young JANG ; Ja Min BYUN ; Sun Hee PARK ; Dong Hyun KIM ; Young Woon CHANG
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2013;13(1):69-72
Coinfection with herpes simplex virus and cytomegalovirus is a very rare cause of esophageal ulcer and upper gastrointestinal hemorrhage. A 26 year-old male kidney transplant recipient was referred with a complaint of melena. Upper gastrointestinal endoscopy showed a huge esophageal ulcer in the anastomosis site of the esophagogastrostomy. The ulcer occupied about two-thirds of the circumference of the esophageal lumen and an exposed vessel in the ulcer base was noted. Pathologic findings with immunohistochemical stain showed co-infection of herpes simplex virus and cytomegalovirus. He was treated successfully with endoscopic hemostasis and antiviral therapy. We report a case of upper gastrointestinal hemorrhage from esophageal ulcer caused by coinfection of herpes simplex virus and cytomegalovirus.
Coinfection
;
Cytomegalovirus
;
Endoscopy, Gastrointestinal
;
Gastrointestinal Hemorrhage
;
Glycosaminoglycans
;
Hemostasis, Endoscopic
;
Herpes Simplex
;
Humans
;
Immunocompromised Host
;
Kidney
;
Male
;
Melena
;
Methylmethacrylates
;
Polystyrenes
;
Simplexvirus
;
Ulcer

Result Analysis
Print
Save
E-mail